Alpha 2.0
Login Register
» Authors » Andrea Freschi

Andrea Freschi

Explore the profile of Andrea Freschi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 222
Followers 0
Related Specialties
Oncology
Genetics
Molecular Biology
Top 10 Co-Authors
Andrea Riccio
Flavia Cerrato
Angela Sparago
Michele Guida
Federica Maria Valente
Marisa S Bartolomei
Ruggero Ridolfi
Lorenzo Gianni
Joanne L Thorvaldsen
Rossana Berardi
Published In
Melanoma Res
Hum Mol Genet
J Clin Oncol
J Hum Genet
Proc Natl Acad Sci U S A
Affiliations
Soon will be listed here.
Recent Articles
11.
(Epi)genotype-phenotype correlations in Beckwith-Wiedemann syndrome
Mussa A, Russo S, De Crescenzo A, Freschi A, Calzari L, Maitz S, et al.
Eur J Hum Genet . 2015 Apr; 24(2):183-90. PMID: 25898929
Beckwith-Wiedemann syndrome (BWS) is characterized by cancer predisposition, overgrowth and highly variable association of macroglossia, abdominal wall defects, nephrourological anomalies, nevus flammeus, ear malformations, hypoglycemia, hemihyperplasia, and organomegaly. BWS molecular...
12.
A splicing mutation of the HMGA2 gene is associated with Silver-Russell syndrome phenotype
De Crescenzo A, Citro V, Freschi A, Sparago A, Palumbo O, Cubellis M, et al.
J Hum Genet . 2015 Mar; 60(6):287-93. PMID: 25809938
Silver-Russell syndrome (SRS) is a heterogeneous disorder characterized by intrauterine and post-natal growth retardation, dysmorphic facial features and body asymmetry. About 50% of the patients carry (epi)genetic alterations involving chromosomes...
13.
Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients
Ridolfi L, Fiorentini G, Guida M, Michiara M, Freschi A, Aitini E, et al.
Melanoma Res . 2009 Mar; 19(2):100-5. PMID: 19262411
The efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 biochemotherapy were evaluated in advanced melanoma patients. The schedule consisted of fotemustine (100 mg/m) and cisplatin (75 mg/m) intravenous on...
14.
Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma
Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, et al.
Melanoma Res . 2006 Jul; 16(4):317-23. PMID: 16845327
Cytokines play a crucial role in the host's immune response. In melanoma patients, cytokine profiles seems to be related to the clinical course and their imbalance could be associated to...
15.
Combined chemoimmunotherapy of metastatic melanoma: a single institution experience
Lauro V, Scalone S, La Mura N, Zanetti M, Nigri P, Freschi A, et al.
Melanoma Res . 2005 May; 15(3):209-12. PMID: 15917704
The addition of cytokines, such as interferon alpha-2b and interleukin-2, to chemotherapy in metastatic melanoma has produced conflicting results in phase II and III trials. We report our experience with...
16.
Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: the experience of a single institution
Libra M, Talamini R, Crivellari D, Buonadonna A, Freschi A, Stefanovski P, et al.
Tumori . 2003 Nov; 89(4):400-4. PMID: 14606643
Aim And Background: Metastatic renal cell carcinoma is one of the few tumors for which a clear benefit of immunotherapy has been demonstrated. The aim of this study was to...
17.
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial
Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, et al.
J Clin Oncol . 2002 Mar; 20(6):1600-7. PMID: 11896110
Purpose: Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR),...